Literature DB >> 8634780

Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis.

S Bosari1, A Marchetti, F Buttitta, D Graziani, G Borsani, M Loda, G Bevilacqua, G Coggi.   

Abstract

p53 mutations are the most common genetic abnormality in humans tumors, but their clinical significance remains to be precisely elucidated. Conventional single-strand conformation polymorphism (SSCP) analysis, a well-established technique for detecting p53 mutations, uses radioactively labeled polymerase chain reaction (PCR) products, which migrate abnormally in the presence of mutations. We performed radioactive PCR-SSCP analysis in a series of 30 formalin-fixed, paraffin-embedded ovarian carcinomas and two cell lines (SW480 and Caov4) harboring known homozygous p53 mutations and compared the results with nonradioactive silver-stained SSCP. The purpose was to assess whether nonradioactive SSCP is suitable for detecting p53 mutations in a rapid, sensitive, cost-effective fashion, without the need of radioactive isotopes. We accomplished PCR amplification of p53 exons 5 through 8 in 26 carcinomas, and radioactive SSCP detected p53 mutations in 13 tumors; three mutations were localized in exon 5, six in exon 6, two in exon 7, and two in exon 8. All mutations were correctly identified with nonradioactive SSCP, except for one exon 8 mutation. To establish the sensitivity of nonradioactive SSCP, DNA samples of SW480 and Caov4 were mixed with increasing amounts (0-90%) of normal DNA and subjected to PCR-SSCP analysis. Mutations were detected until the concentration of SW480 and Caov4 was 15% and 10%, respectively, of the total sample. The results of our investigation demonstrate that nonradioactive silver-stained SSCP is a sensitive, rapid, and simple technique to detect p53 mutations, even in formalin-fixed tissues, and could be easily used to investigate large series of patients to assess the clinical significance of p53 mutations in human tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8634780     DOI: 10.1097/00019606-199512000-00004

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  14 in total

1.  Structural and numerical chromosome changes in colon cancer develop through telomere-mediated anaphase bridges, not through mitotic multipolarity.

Authors:  Ylva Stewénius; Ludmila Gorunova; Tord Jonson; Nina Larsson; Mattias Höglund; Nils Mandahl; Fredrik Mertens; Felix Mitelman; David Gisselsson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

2.  Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.

Authors:  Guo Jian; Zhou Songwen; Zhang Ling; Deng Qinfang; Zhang Jie; Tang Liang; Zhou Caicun
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-14       Impact factor: 4.553

Review 3.  Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.

Authors:  Xiaozhu Zhang; Alex Chang
Journal:  J Med Genet       Date:  2006-12-08       Impact factor: 6.318

4.  Developmental stage-specific imprinting of IPL in domestic pigs (Sus scrofa).

Authors:  Shengping Hou; Yuming Chen; Jie Liang; Li Li; Tongshan Wu; X Cindy Tian; Shouquan Zhang
Journal:  J Biomed Biotechnol       Date:  2010-06-02

5.  Lack of mutational events of RAS genes in sporadic thyroid cancer but high risk associated with HRAS T81C single nucleotide polymorphism (case-control study).

Authors:  Mosin S Khan; Arshad A Pandith; Mahboob Ul Hussain; Mohammad Iqbal; Nighat P Khan; Khurshid A Wani; Shariq R Masoodi; Syed Mudassar
Journal:  Tumour Biol       Date:  2012-11-13

6.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

7.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

Review 8.  The clinical significance of p53 aberrations in human tumours.

Authors:  S Bosari; G Viale
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Change of the protein p53 electrochemical signal according to its structural form - quick and sensitive distinguishing of native, denatured, and aggregated form of the "guardian of the genome".

Authors:  David Potesil; Radka Mikelova; Vojtech Adam; Rene Kizek; Richard Prusa
Journal:  Protein J       Date:  2006-01       Impact factor: 4.000

10.  Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area.

Authors:  A Syed Sameer; Shakeel ul Rehman; Arshad A Pandith; Nidda Syeed; Zaffar A Shah; Nissar A Chowdhri; Khursheed A Wani; Mushtaq A Siddiqi
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.